相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions
Ahmad I. Antar et al.
LEUKEMIA (2020)
3,5,7-Substituted Pyrazolo[4,3-d]pyrimidine Inhibitors of Cyclin-Dependent Kinases and Their Evaluation in Lymphoma Models
Radek Jorda et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Discovery of N2-(4-Amino-cyclohexyl)-9-cyclopentyl-N6-(4-morpholin-4-ylmethyl-phenyl)-9H-purine-2,6-diamine as a Potent FLT3 Kinase Inhibitor for Acute Myeloid Leukemia with FLT3 Mutations
Tomas Gucky et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor
Lauren Y. Lee et al.
BLOOD (2017)
Design, synthesis and biological evaluation of novel azaspiro analogs of linezolid as antibacterial and antitubercular agents
Pradip K. Gadekar et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Discovery and SAR of novel pyrazolo[1,5-a]pyrimidines as inhibitors of CDK9
Louisa J. Phillipson et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2015)
Design, synthesis and biological evaluation of paclitaxel-mimics possessing only the oxetane D-ring and side chain structures
Xing-Xiu Chen et al.
FITOTERAPIA (2014)
The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond
Seth A. Wander et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2014)
Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia
Eric I. Zimmerman et al.
BLOOD (2013)
Synthesis and in vitro biological evaluation of 2,6,9-trisubstituted purines targeting multiple cyclin-dependent kinases
Marek Zatloukal et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2013)
A Novel Series of Highly Potent 2,6,9-Trisubstituted Purine Cyclin-Dependent Kinase Inhibitors
Tomas Gucky et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies
Da Zhang et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Cyclin-dependent kinase Inhibitors Inspired by Roscovitine: Purine Bioisosteres
Radek Jorda et al.
CURRENT PHARMACEUTICAL DESIGN (2012)
The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells
A. J. Johnson et al.
LEUKEMIA (2012)
Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program
Richard Gorlick et al.
PEDIATRIC BLOOD & CANCER (2012)
FLT3 Inhibitors in the Treatment of Acute Myeloid Leukemia The Start of an Era?
Naveen Pemmaraju et al.
CANCER (2011)
Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
David Parry et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases
Kamil Paruch et al.
ACS MEDICINAL CHEMISTRY LETTERS (2010)
Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor
Frank Breitenbuecher et al.
BLOOD (2009)
Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome
Sabine Kayser et al.
BLOOD (2009)
Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia
DL Stirewalt et al.
BLOOD (2006)
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
Y Yamamoto et al.
BLOOD (2001)
分享论文
